Evidence map›Paper›PMID 28753106›Full record

ArticleEpigenetics2017

Colorectal adenoma and cancer detection based on altered methylation pattern of SFRP1, SFRP2, SDC2, and PRIMA1 in plasma samples.

Barbara Kinga Barták, Alexandra Kalmár, Bálint Péterfia, Árpád V Patai, Orsolya Galamb, Gábor Valcz, Sándor Spisák, Barnabás Wichmann, Zsófia Brigitta Nagy, Kinga Tóth and 3 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Epigenetics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 72 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
72citing papers in PubMed, 4 pooled it
4.4field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

72 citing papers in PubMed, 4 syntheses or guidelines pooled it, 113 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review: Detection of Cancer Biomarkers from a Clinical Perspective.International journal of molecular sciences · 2025
    Review
  12. Review
  13. Article
  14. Article
  15. Review
  16. Review
  17. Observational
  18. Review
  19. Review
  20. Review

12 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 2 countries.

Barbara Kinga Bartáka 2nd Department of Internal Medicine , Semmelweis University , H-1088 Budapest , Hungary.
Alexandra Kalmára 2nd Department of Internal Medicine , Semmelweis University , H-1088 Budapest , Hungary.ORCID 0000-0002-3824-1534
Bálint Péterfiaa 2nd Department of Internal Medicine , Semmelweis University , H-1088 Budapest , Hungary.ORCID 0000-0001-9090-9979
Árpád V Pataia 2nd Department of Internal Medicine , Semmelweis University , H-1088 Budapest , Hungary.
Orsolya Galambb Molecular Medicine Research Group, Hungarian Academy of Sciences , H-1088 Budapest , Hungary.ORCID 0000-0002-7042-5667
Gábor Valczb Molecular Medicine Research Group, Hungarian Academy of Sciences , H-1088 Budapest , Hungary.ORCID 0000-0002-7109-3529
Sándor Spisákc Department of Medical Oncology , Dana-Farber Cancer Institute , Boston , Massachusetts , USA.
Barnabás Wichmannb Molecular Medicine Research Group, Hungarian Academy of Sciences , H-1088 Budapest , Hungary.ORCID 0000-0002-2320-8459
Zsófia Brigitta Nagya 2nd Department of Internal Medicine , Semmelweis University , H-1088 Budapest , Hungary.
Kinga Tótha 2nd Department of Internal Medicine , Semmelweis University , H-1088 Budapest , Hungary.ORCID 0000-0002-5405-718X
Zsolt Tulassaya 2nd Department of Internal Medicine , Semmelweis University , H-1088 Budapest , Hungary.
Péter Igaza 2nd Department of Internal Medicine , Semmelweis University , H-1088 Budapest , Hungary.ORCID 0000-0003-2192-554X
Béla Molnárb Molecular Medicine Research Group, Hungarian Academy of Sciences , H-1088 Budapest , Hungary.ORCID 0000-0001-5147-1273
Semmelweis University · HUHungarian Academy of Sciences · HUDana-Farber Cancer Institute · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Aberrant methylation is one of the most frequent epigenetic alterations that can contribute to tumor formation. Cell-free DNA can originate from tumor tissue; therefore, the evaluation of methylation markers in cell-free DNA can be a promising method for cancer screening. Our aim was to develop a panel of biomarkers with altered methylation along the colorectal adenoma-carcinoma sequence in both colonic tissue and plasma. Methylation of selected CpG sites in healthy colonic (n = 15), adenoma (n = 15), and colorectal cancer (n = 15) tissues was analyzed by pyrosequencing. MethyLight PCR was applied to study the DNA methylation of SFRP1, SFRP2, SDC2, and PRIMA1 gene promoters in 121 plasma and 32 biopsy samples. The effect of altered promoter methylation on protein expression was examined by immunohistochemistry. Significantly higher (P < 0.05) DNA methylation levels were detected in the promoter regions of all 4 markers, both in CRC and adenoma tissues compared with healthy controls. Methylation of SFRP1, SFRP2, SDC2, and PRIMA1 promoter sequences was observed in 85.1%, 72.3%, 89.4%, and 80.9% of plasma samples from patients with CRC and 89.2%, 83.8%, 81.1% and 70.3% from adenoma patients, respectively. When applied as a panel, CRC patients could be distinguished from controls with 91.5% sensitivity and 97.3% specificity [area under the curve (AUC) = 0.978], while adenoma samples could be differentiated with 89.2% sensitivity and 86.5% specificity (AUC = 0.937). Immunohistochemical analysis indicated decreasing protein levels of all 4 markers along the colorectal adenoma-carcinoma sequence. Our findings suggest that this methylation biomarker panel allows non-invasive detection of colorectal adenoma and cancer from plasma samples.

Indexed as

DNA MethylationAdenomaBiomarkers, TumorColorectal NeoplasmsGene Expression Regulation, NeoplasticHumansImmunohistochemistryIntercellular Signaling Peptides and ProteinsMembrane ProteinsNerve Tissue ProteinsPromoter Regions, GeneticSecreted Frizzled-Related ProteinsSyndecan-2Biomarkers, TumorIntercellular Signaling Peptides and ProteinsMembrane ProteinsNerve Tissue ProteinsPRIMA1 protein, humanSDC2 protein, humanSecreted Frizzled-Related ProteinsSFRP1 protein, humanSFRP2 protein, humanSyndecan-2Adenomabiomarkercell-free DNAcolorectal cancerDNA methylationliquid biopsyplasma

Identifiers

PMID28753106
PMCPMC5739100
OpenAlexW2739520683

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.